Applied Genetic Technologies Corporation
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AGTC research report →
Companyagtc.com
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase 1/2 clinical trials; and achromatopsia that is in Phase 1/2 clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease.
- CEO
- Susan Washer
- IPO
- 2014
- Employees
- 102
- HQ
- Alachua, FL, US
Price Chart
Valuation
- Market Cap
- $0
- P/E
- -0.25
- P/S
- 0.00
- P/B
- 0.60
- EV/EBITDA
- 0.37
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 100.00%
- Op Margin
- -20390.46%
- Net Margin
- -21976.62%
- ROE
- -123.91%
- ROIC
- -127.33%
Growth & Income
- Revenue
- $325.00K · -35.00%
- Net Income
- $-71,424,000 · -23.51%
- EPS
- $-1.59 · 10.17%
- Op Income
- $-66,269,000
- FCF YoY
- -27.77%
Performance & Tape
- 52W High
- $2.83
- 52W Low
- $0.23
- 50D MA
- $0.35
- 200D MA
- $0.67
- Beta
- 1.58
- Avg Volume
- 1.32M
Get TickerSpark's AI analysis on AGTC
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 30, 22 | Robinson James A. Jr. | sell | 25,000 |
| Nov 30, 22 | VANLENT ANNE | sell | 14,000 |
| Nov 30, 22 | Rosen James | other | 1,000 |
| Nov 30, 22 | Rosen James | sell | 14,000 |
| Nov 30, 22 | Aliski William | other | 8,500 |
| Nov 30, 22 | Aliski William | sell | 14,000 |
| Nov 30, 22 | HURWITZ EDWARD | other | 1,800 |
| Nov 30, 22 | HURWITZ EDWARD | sell | 14,000 |
| Nov 30, 22 | Hashad Yehia | sell | 14,000 |
| Nov 30, 22 | Koenig Scott | sell | 14,000 |
Our AGTC Coverage
We haven't published any research on AGTC yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate AGTC Report →